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Abstract
Introduction: Trastuzumab, a recombinant humanized monoclonal antibody, is
targeted against the external domain of the human epidermal growth factor
receptor type 2 (HER2). It improves efficacy of HER2-positive breast cancer treat-
ment. The authors present their experience with patients (pts) treated with
trastuzumab in the aspects of cardiac complications.
Material and methods: We observed prospectively 253 women with early posi-
tive HER2 breast cancer treated with trastuzumab. Assessment of cardiovascu-
lar status, ECG and echocardiography was performed initially and every 3 months
until 6th month during follow-up.
Results: Cardiac complications developed in 52 pts (20.55%) and included:
asymptomatic left ventricle dysfunction (43), symptomatic heart failure (6), new
asymptomatic LBBB (1); new negative T-waves in ECG (2). There was a pro-
gressive decline in left ventricular ejection fraction (LVEF) during treatment. It
was more enhanced in pts with cardiac complications. Following trastuzumab
termination/discontinuation LVEF increased but at month 18 still remained sig-
nificantly lower than initially in both groups (61.07 ±4.84 vs. 59.97 ±5.23 – no
cardiac complications; p < 0.05; 58.14 ±4.08% vs. 53.08 ±5.74% – cardiac com-
plications; p < 0.05). During 6-month follow-up 33 out of 46 pts experienced an
improvement in left ventricular status. In 13 pts in whom trastuzumab was dis-
continued, it was restarted; 6 of them successfully completed total therapy. Uni-
variate analysis revealed no association between any cardiovascular risk factor
and the development of cardiotoxicity.
Conclusions: One out of five treated patients discontinues trastuzumab in an
adjuvant setting due to cardiac complications. LV dysfunction is the most fre-
quent. Routine cardiac monitoring should be obligatory.
Key words: trastuzumab, cardiotoxicity, trastuzumab-related cardiomyopathy, breast
cancer, HER2 overexpression.
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Introduction
Breast cancer is the most frequent cancer in
women and the leading cause of cancer-related
deaths. In 20-30% of invasive breast cancers over-
expression of human epidermal growth factor
receptor type 2 (HER2) occurs, which is associated
with a poor prognosis [1, 2]. Trastuzumab is a hu  -
manized monoclonal antibody that binds to the
extracellular domain of HER2 receptor and inhibits
carcinoma cellular proliferation [3]. Four large mul-
ticenter randomized trials revealed that trastuzum-
ab in HER2-positive early breast cancer added to
anthracycline, cyclophosphamide or paclitaxel
chemotherapy resulted in 50% reduction in 3-year
risk of recurrence and over 30% reduction in the
death rate [4-6]. These benefits were recently con-
firmed by longer follow-ups [7].
But the efficacy of trastuzumab is at the cost of
significant cardiotoxicity, which manifests usually
as either asymptomatic left ventricular dysfunction
or as symptomatic heart failure (HF). The incidence
of cardiotoxicity was highest in patients receiving
concurrent trastuzumab and anthracyclines (27%)
with lower risk in patients receiving trastuzumab
plus paclitaxel (13%) or trastuzumab alone (3-7%)
(in metastatic disease) [8]. Now trastuzumab is rec-
ommended to use following, but not concurrently,
anthracycline therapy to minimize cardiotoxicity. 
As trastuzumab-associated cardiotoxicity is not
well defined and its nature is not understood but
often limits scheduled breast cancer treatment, we
present our prospective observation of patients
treated with trastuzumab in an adjuvant setting in
the aspects of cardiac complications.
Material and methods
The study included 253 consecutive patients with
early breast cancer, qualified for trastuzumab adju-
vant chemotherapy, who were referred to our echo-
laboratory from 1 March 2008 to 30 June 2011 for 
2-dimensional echocardiography and who met the
inclusion criteria. The inclusion criteria followed clin-
ical guidelines [9, 10] and were histologically con-
firmed invasive HER2 positive breast cancer and
LVEF > 50%. The patients were excluded if they had
metastatic disease, symptoms of heart failure, LVEF
< 50%, had myocardial infarction 6 months previ-
ously, or presented uncontrolled symptomatic angi-
na pectoris, uncontrolled arrhythmia, uncontrolled
hypertension or any significant valvular heart dis-
ease (mitral or aortic insufficiency).
Each participant of the study signed informed
consent. The protocol was approved by the local
Ethics Committee.
Cardiovascular system evaluation (history, car-
diovascular risk factors, blood pressure and physi-
cal examination), electrocardiography and echocar-
diography were performed at baseline and repeat-
ed every 3 months until 6 months after trastuzum-
ab termination. It was performed and interpreted
by the same experienced cardiologist (GP). Paraster-
nal and apical views were obtained using a stan-
dard echocardiograph (GE VIVID 4, transducer 
1.7-4.0 MHz, USA). Left ventricular ejection fraction
(LVEF) was determined from two-dimensional
images according to established criteria including
modified Simpson’s method [11]. 
The following cardiovascular risk factors were
ana  lysed: age, overweight (body mass index 
– BMI > 25 kg m2 and < 30 kg/m2), obesity (BMI 
> 30 kg/m2), hypertension, smoking, sedentary
lifestyle, positive family history, hypercholestero-
laemia, diabetes mellitus, depression.
All patients were diagnosed with histologically
confirmed, completely excised invasive breast can-
cer with HER2 overexpression, fulfilling criteria for
adjuvant therapy with trastuzumab. Trastuzumab
was initiated after completion of chemo- and radio-
therapy. The loading administration dose of
trastuzumab was 8 mg/kg of body weight, and the
maintenance dose was 6 mg/kg triweekly for a total
of 52 weeks. Trastuzumab was discontinued in
patients who developed significant cardiotoxicity,
which was defined as a potentially life-threatening
cardiac event. Anthracycline-containing regimens
used as adjuvant or neoadjuvant chemotherapy
were AC (doxorubicin 60 mg/m2 and cyclophos-
phamide 600 mg/m2, every 3 weeks for four cycles)
or in 7 patients FEC (fluorouracil 500 mg/m2, 
epirubicin 100 mg/m2, and cyclophosphamide 
600 mg/m2, every 3 weeks for more than four
cycles). Docetaxel was given at 60-75 mg/m2 tri-
weekly. Endocrine therapy was added as clinically
indicated on the basis of tumour characteristics.
Radiotherapy was administered in 159 (62.9%) indi-
viduals and neoadjuvant therapy according to the
AT protocol was applied in 70 patients (27.7%).
HER2 status was determined by immunohisto-
chemical staining (3+) or in case of HER2 result 2++
amplification of the HER2 gene was evaluated using
the fluorescence in situ hybridization (FISH) method. 
Cardiotoxicity
Significant cardiotoxicity was regarded as
a potentially life-threatening cardiac event and was
defined as: (1) each absolute decrease of LVEF > 15%
[12], (2) absolute reduction in LVEF of 10% from the
baseline value and below the level of 50% [5], 
(3) any symptoms or signs of heart failure. As oth-
er events that occur in the cardiovascular system
during trastuzumab treatment are rare and not well
known, they were not defined precisely in advance,
but were evaluated individually by the cardiologist
and oncologist together in the course of the treat-
ment. In case of significant cardiotoxicity trastu  -Arch Med Sci 2, April / 2012 229
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer 
overexpressing human epidermal growth factor receptor type 2 – a prospective study
zumab was terminated early. The decision regard-
ing discontinuation of trastuzumab was made
according to guidelines [9, 10] and each time it was
made individually by the oncologist responsible for
the treatment after consultation with the supervis-
ing cardiologist. In the majority of cases of signifi-
cant cardiotoxicity, trastuzumab was discontinued,
and heart failure (HF) treatment with angiotensin-
converting enzyme inhibitors/angiote-nsin receptor
antagonists (ACE-I/ARA) and/or β-blockers was ini-
tiated and up-titrated to the maximum tolerated
doses. Additional cardiac treatment, including diuret-
ics, anticoagulants, and antiarrhythmic drugs, was
given as required by the clinical situation, based on
the current standard of care [13]. 
Statistical analysis
Data were reported as mean ± SD. Comparisons
between groups were done by unpaired Student’s
t-test for continuous variables and by χ2 test or
Fisher’s exact test as appropriate for categorical
variables. Univariate regression analysis was used
to identify covariates of cardiotoxicity. Statistical
Analysis Systems (SPSS PC and Statistica) were
used to perform the analysis. A p value less than
0.05 was considered significant.
Results
Two hundred and fifty-three women entered the
study (mean age: 55 ±10 years), which was 60.19%
of the total (420 women) population treated with
trastuzumab in our centre from 1 March 2008 to 
30 June 2011. Fourty-seven patients (11.1%) did not
fulfil the entry criteria (initial LVEF < 50%) or had
contraindications to trastuzumab therapy (advanced
heart diseases), 18 (4.3%) refused to participate in
the study, and 5 patients (1.2%) were not included
because of extremely poor quality of the echocar-
diographic image. The remaining women were diag-
nosed with metastatic cancer or had echocardiog-
raphy performed outside our centre. After 3 months
241, after 6 months 239, after 9 months 205, and
after 12 months 142 patients had echocardiography
performed. At follow-up visits at 3 and 6 months
after trastuzumab termination 124 and 101 patients
were assessed, respectively.
The duration of trastuzumab treatment differed
between groups with and without cardiac compli-
cations. In the population with cardiac complications,
the mean duration of treatment with trastuzumab
was 25.3 weeks (from to 4 to 52 weeks) and for the
population with no complications 51.2 weeks (from
49.3 to 53.9 weeks).
Serious cardiac complications that resulted in
early trastuzumab termination occurred in 52
patients (20.55%). Among cardiac complications
associated with trastuzumab, asymptomatic left
ventricle (LV) dysfunction was the most frequent,
whereas severe, symptomatic heart failure (HF)
(New York Heart Association [NYHA] functional class
III/IV), new asymptomatic left bundle branch block
(LBBB), new negative T-waves in electrocardiogra-
phy (ECG) and asymptomatic right bundle branch
block (RBBB) were observed much more rarely
(Table I). Severe HF (NYHA III/IV) occurred in 
6 patients (2.37%) – in 3 associated with LV systolic
dysfunction while in 3 others LV systolic function
was preserved.
Negative T waves resumed after 6 months in
both patients. Nuclear stress testing (GSPECT) was
negative for ischaemia, echocardiography demon-
strated no abnormalities of LV wall motion, and
sequential cardiac troponin tests were negative. The
LBBB was still present and still asymptomatic at
the moment of the publication. This patient is still
under observation in our cardiology department.
Six patients with overt HF fully recovered after dis-
continuation of trastuzumab and implementation
of heart failure therapy (ACE-I, β-blockers, tem-
porarily diuretics) within 6 months of observation.
All patients had no symptoms of heart failure at
baseline. Mean LVEF at baseline was 60.52 ±4.85%.
Mean LVEF was significantly lower in the group with
cardiac complications (58.14 ±4.08 vs. 61.07 ±4.84,
p < 0.05). After 3 months of trastuzumab therapy,
Reason for early trastuzumab termination Patients (N = 253)
n %
Cardiac complications 52 20.55
Asymptomatic LV dysfunction 43 17
Severe, symptomatic HF 6 2.37
Asymptomatic, new LBBB 1 0.4
Negative T waves V1-6 in ECG 2 0.79
Breast cancer recurrence (during trastuzumab treatment) 27 10.67
Patient withdrawal 16 6.32
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there was a difference in LVEF between the no car-
diac complication cohort and those patients 
in whom cardiac complications developed (59.18
±4.83% vs. 51.59 ±6.63%, p < 0.05). There was a pro-
gressive decline in LVEF up to 12 months in both
groups, but it was more enhanced in the group with
cardiac complications despite the fact that they
were exposed to the medication for a shorter peri-
od. At 12 months LVEF stabilized at 56.92 ±5.17 in
the group with no cardiac complications and at
43.79 ±2.67% in the group with cardiac complica-
tions, which was a significant difference (p < 0.05).
Following trastuzumab termination/discontinuation
LVEF increased but still remained at month 18 sig-
nificantly lower in both groups as compared with
baseline status (61.07 ±4.84 vs. 59.97 ±5.23 – no
cardiac complications; p < 0.05; 58.14 ±4.08 vs.
53.08 ±5.74 – cardiac complications; p < 0.05;
respectively) (Figure 1, Table II). The same drop of
LVEF from baseline to 6 months after discontinua-
tion of trastuzumab was observed for the whole
study group (Table II). 
Median time of trastuzumab early termination
due to all kinds of cardiac complications was 
25.3 weeks (from 4 to 52 weeks). Median time of
trastuzumab early termination due to significant
LV systolic dysfunction was 26.2 weeks (from 4 to
52 weeks). Trastuzumab was discontinued in 
13 patients (including 1 due to new onset LBBB)
after 3 months, in 22 (including 2 due to ST-T repo-
larization disturbances and 3 due to overt HF) after
6 months, in 12 (including 2 due to overt HF) after
9 months. A significant drop in LVEF was observed
after 12 months in 5 patients (including 1 with overt
HF). Trastuzumab was discontinued after a mean
of 8 ±4 doses.
The majority of patients with cardiac complica-
tions during trastuzumab therapy were asympto-
matic (88.5%). Six patients (2.37%) presented with
dyspnoea (NYHA III/IV). Out of 46 patients with LV
dysfunction 43 (93.5%) received heart failure med-
ications including ACE inhibitors and/or β-blockers.
Eleven patients (23.9%) were on ACE I, 10 (21.7%)
on β-blockers alone and 22 (47.8%) were on both
medications. Three patients did not receive any
heart failure treatment. In 9 patients (19.6%) diuret-
ics were applied and in 9 (19.6%) aldosterone antag-
onist (eplerenone in 1 and spironolactone in the
others). 
At 6 months follow-up 33 (71.7%) out of 46 pa  -
tients experienced a demonstrable improvement
(LVEF > 50%) in left ventricular status. In the 
13 (28.26%) remaining individuals LVEF was still
below 50% after 6 months, 9 (19.6%) of them
showed no significant improvement in mean LVEF
(37.4%) and in 4 (8.7%) there developed a further
decline in mean LVEF (35.6%). Median recovery time
for 33 patients with LV systolic function improve-
ment was 9 weeks (from 4 to 28 weeks). 
In 13 patients (28.26%) in whom trastuzumab
was discontinued due to LVEF drop, trastuzumab
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Figure 1. Serial monitoring of LVEF in patients with
no cardiac complications compared to those with
cardiac complications
Duration of trastuzumab treatment and follow-up observation
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No cardiac complications Cardiac complications
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Time of  Total  Group with  Group with Value of p
measurement population no cardiac cardiac No complications vs.
LVEF [%] complications complications complications
LVEF [%] LVEF [%]
Baseline 60.52 ±4.85 61.07 ±4.84 58.14 ±4.08 0.00024
3 months 57.72 ±6.03 59.18 ±4.83 51.59 ±6.63 < 0.001
6 months 56.87 ±6.62 58.66 ±4.74 47.92 ±7.06 < 0.001
9 months 57.1 ±6.23 58.28 ±4.91 46.46 ±5.58 < 0.001
12 months 55.55 ±6.41 56.92 ±5.17 43.79 ±2.67 < 0.001
15 months 56.15 ±7.33 58.53 ±6.41 50.96 ±6.58 < 0.001
18 months 57.87 ±6.27 59.97 ±5.23 53.08 ±5.74 < 0.001
Table II. LVEF in total population, in group with and without cardiac complications at particular time of measure-
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was restarted with concomitant use of ACE inhibi-
tion and β-blockade. In 6 of them, total 12-month
therapy was successfully completed with no recur-
rence of LV systolic dysfunction. In 7 others
trastuzumab was discontinued again due to recur-
rence of LV systolic dysfunction and in those
patients the therapy was not restarted again.
In 28 (60.9%) out of 46 patients with LV systolic
dysfunction regional wall motion abnormalities
were observed in the first echocardiography that
revealed a significant drop of LVEF. In the majority,
regional hypokinesis concerned the interventricu-
lar septum – 18 patients (64.29%). In 10 patients
(39.1%) general hypokinesis with no regional wall
motion abnormalities was observed initially. How-
ever, in the majority of cases, subsequent echocar-
diographies showed general hypokinesis despite
initial regional abnormalities detected at the begin-
ning.
Cardiovascular risk factors
As shown in Table III, there were no significant
differences in prevalence of cardiovascular risk fac-
tors between the group of patients with and with-
out cardiac complications. There was relatively high
prevalence of hypertension (39.1%), particularly in
the group of patients who developed cardiac com-
plications (42.3%) and high prevalence of diabetes
mellitus (6.3%). Numerous patients were over-
weight (39.1%), and sedentary (76.7%). Sedentary
women were especially frequent in the group with
cardiac complications (82.7%). The prevalence of
hypercholesterolaemia (34.4%) and smoking (13.4%)
seems to be relatively low (Table III).
In univariate logistic regression none of the
analysed cardiovascular risk factors (age, obesity,
hypertension, smoking, sedentary lifestyle, positive
family history, hypercholesterolaemia, diabetes mel-
litus, depression) was associated with significant
cardiotoxicity (Table IV). 
Discussion
Cardiotoxicity of the treatment in oncology often
limits its benefits [14]. This is why monitoring and
early prevention of aggressive anti-tumour treat-
ment cardiac complications is of clinical interest. 
The current study provides insight into the com-
mon experience of trastuzumab use in real life sit-
uations common in oncology and cardiology clin-
ics. In that aspect, it differs from most published
clinical trials. In a prospectively evaluated popula-
tion of 253 HER2 positive, early breast cancer
women treated with trastuzumab in the adjuvant
setting, nearly 21% required discontinuation of the
medication due to cardiac complications. In 18% of
patients significant LV systolic dysfunction was the
reason for trastuzumab discontinuation. The major-
ity of complications were asymptomatic. Only 
6 patients complained of significant shortness of
breath, and 3 of them had preserved LV systolic
function. 
The asymptomatic nature of cardiac complica-
tions makes monitoring of trastuzumab therapy
safety necessary. This issue has been addressed
Risk factors Total population Group with  Group with Value of p
(N = 253) no cardiac  cardiac No complications
complications complications vs. complications
(n = 201) (n = 52)
Age [years] 55 ±10  54.8 ±9.7 56.8 ±9.6 0.366
BMI [kg/m2] 26.8 ±4.5 26.9 ±4.6 27.3 ±4.4 0.417
Hypertension 99 (39.1%) 77 (38.3%) 22 (42.3%) 0.327
Diabetes mellitus 16 (6.3%) 13 (6.47%) 3 (5.8%) 0.952
Smoking 27 (13.4%) 27 (13.4%) 7 (13.5%) 0.841
Hypercholesterolaemia 87 (34.4%) 70 (34.8%) 17 (32.7%) 0.931
Sedentary life style 194 (76.7%) 151 (75.1%) 43 (82.7%) 0.109
Overweight (≤ 25 BMI < 30) [kg/m2] 99 (39.1%) 80 (39.8%) 19 (36.5%) 0.864
Obesity (BMI ≥ 30) [kg/m2] 59 (23.3%) 46 (22.9%) 13 (25.0%) 0.410
Depression 28 (11.1%) 21 (10.5%) 7 (13.5%) 0.523
Positive family history 88 (34.8%) 68 (33.8%) 20 (38.5%) 0.321
ACE-I/ARA (at baseline) 78 (30.8%) 62 (30.9%) 16 (30.8%) 0.172
β-Blockers (at baseline) 22 (8.7%) 18 (9%) 4 (7.8%) 0.649
Coronary artery disease 10 (4%) 10 (5%) 0 (0%) 1.000
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and regulated by a few guidelines [9, 10]. They sug-
gest that detection of heart damage due to
trastuzumab therapy is best accomplished via
sequential measurements of LV function, either by
multiple-gated acquisition scans (MUGA) or by
echocardiography techniques. In addition to imag-
ing methods, the literature suggests that meas-
urement of plasma markers, such as brain natri-
uretic peptide (BNP) as a marker of LV stretch and
cardiac troponins as markers of myocardium disin-
tegration, may be used to predict and to detect car-
diac dysfunction during treatment with trastuzum-
ab [15].
Other non-myopathic cardiac complications
associated with trastuzumab therapy were: LBBB
in 1, negative T-waves in 2, RBBB in 2 patients. They
were rare, all asymptomatic and the last one was
not the reason for trastuzumab discontinuation.
The authors found a few instances of non-myo-
pathic cardiac events after trastuzumab specifical-
ly described. There was a case of a 19-year-old
woman, in whom during infusion of the fifth dose
of trastuzumab chest pain occurred and ECG
revealed new T wave inversions in the anterior pre-
cordial and lateral leads [16]. There were two exam-
ples of heart conduction abnormalities after
trastuzumab [17] and there was also a report about
ventricular tachycardia associated with trastuzum-
ab in a patient with preserved LV systolic function
that resulted in sudden cardiac death [18].
The incidence of left ventricular dysfunction in
our study is consistent with that reported in the
BCIRG 006 trial (18%) [19] and is higher than in the
HERA trial (3.05%) [5]. It is slightly less than in ret-
rospective observations by Wadhwa et al. [20],
Tarantini et al. [21] and McArthur and Chia [22], who
reported 24%, 23% and 22% LV systolic dysfunction
during trastuzumab treatment, respectively. 
The incidence of LV dysfunction during tras  -
tuzumab treatment has usually been reported high-
er in a metastatic (up to 34%) [23, 24] than in an
adjuvant [25, 26] setting. The incidence of car-
diotoxicity seems to be higher outside of clinical tri-
als, in observational studies like ours.
The differences in the incidence of LV dysfunc-
tion in our and other clinical observations might
have resulted from the fact that different defini-
tions of cardiotoxicity were used in particular trials.
For example, Wadhwa et al. defined cardiotoxicity
as a decline in LVEF of at least 10% and below 55%
and not below 50% as in our study [20], which
might be one of the reasons for higher LV dys-
function incidence in his report.
Symptomatic heart failure events have been
observed much less frequently than asymptomatic
LV dysfunction. 1.9% in BCIRG (Breast Cancer Inter-
national Research Group) 006, 4% in NSABP
(National Surgical Adjuvant Cancer Treatment
Group) B-31 and 0.6% in the HERA (HERceptin Adju-
vant) trial of trastuzumab-treated patients report-
ed severe symptoms of HF (NYHA III/IV) [5]. Taran-
tini et al. reported 3% symptomatic heart failure
incidence in a cohort of 499 women with HER pos-
itive early breast cancer from 10 Italian institutions
treated with trastuzumab observed retrospective-
ly [20]. But all women in this observation were in
NYHA functional class II. Such incidence is consis-
tent with that in our study, in which 2.37% of
patients complained of severe HF symptoms. 
The majority of complications were observed
between the 3rd and 6th month (mean after 8 ±4
doses) but later they occurred as well. An LVEF drop
Independent covariates OR –95% CI +95% CI Value of p
Age 1.02 0.99 1.06 0.197
BMI 1.02 0.95 1.09 0.564
Hypertension 1.38 0.72 2.64 0.328
Diabetes mellitus 0.96 0.26 3.52 0.952
Smoking 0.96 0.75 1.24 0.771
Hypercholesterolaemia 1.03 0.53 2.01 0.931
Sedentary life style 2.63 0.77 9.09 0.122
Overweight (≤25 BMI < 30) [kg/m2] 1.13 0.57 1.78 0.243
Obesity (BMI ≥ 30) [kg/m2] 1.35 0.66 2.78 0.411
Depression 1.35 0.54 3.40 0.524
Positive family history 1.39 0.72 2.68 0.322
ACE-I/ARA (at baseline) 1.07 0.66 1.99 0.456
β-Blockers (at baseline) 1.16 1.19 1.40 0.329
Table IV. Associations between dependent variable: cardiac complications vs. no cardiac complications and group 
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that fulfilled the criteria of significant cardiotoxici-
ty was observed after 12 month in 5 patients. In the
retrospective study by Wadhwa et al. mean dura-
tion of treatment for the population with LV dys-
function was 25.7 ±12.9 weeks, which is consistent
with the duration of treatment for that group in our
observation – 25 ±12 weeks [20]. In the NSABP-3
trial, the majority of patients developed cardiac
complications between the 3rd and 12th month [27],
whereas in the population observed by Tarantini 
et al. LV dysfunction was detected mainly during
the first 3 months of therapy with a stable trend
thereafter (5% new LV dysfunction episodes every 
3 months during therapy) [10]. 
We found no differences in prevalence of car-
diovascular risk factors between the group of
patients with and without cardiac complications.
Also no risk factor was associated with cardiotoxi-
city in univariate logistic regression analysis. It
might be surprising, as the presence of pre-exist-
ing cardiovascular risk factors is regarded as a pre-
dictor for the development of therapy-induced car-
diovascular injury. However, the association of
cardiovascular risk factors with trastuzumab-relat-
ed cardiotoxicity is not apparent and not fully
explained. Particular trials have obtained different
results for particular cardiovascular risk factors. 
In the NSABP B-31 and NCTTG N9831 trials age 
≥ 50 years and requirement for hypertension med-
ications were risk factors for heart failure in the
course of trastuzumab treatment in univariate
analysis [27, 28]. In the NSABP B-31 trial there was
no association between trastuzumab-mediated car-
diotoxicity and smoking, positive family history, or
hypoglycaemic and hypolipaemic medications [27].
In the HERA trial overweight and obesity were risk
factors for cardiac toxicity but age, hypertension,
dyslipidaemia and previous heart disease did not
increase the risk of trastuzumab-related cardiotox-
icity [25]. Age, smoking and hypertension were inde-
pendent predictors of trastuzumab-related car-
diomyopathy in Wadhwa’s observational study [20].
Nevertheless, in the retrospective study by Taran-
tini et al. [21], as in ours, no traditional risk factor
(age, body mass index, systemic hypertension, dia-
betes mellitus) was associated with the develop-
ment of trastuzumab-induced cardiotoxicity. 
Women with breast cancer are regarded as
a population of high cardiovascular risk [29].
Women with breast cancer are often sedentary [30],
overweight and obese [31]. Heart diseases and
breast cancer have many cardiovascular risk factors
in common. Recent data suggest that physical inac-
tivity increases the risk of breast cancer among
white women by 2% to 15% [32], while overweight
and obesity are associated with 34% and 63%
increase of breast cancer risk, respectively [33]. This
is consistent with our observation, in which numer-
ous patients were overweight (39.1%) and were
sedentary (76.7%), especially in the group with car-
diac complications (82.7%). There was also relatively
high prevalence of hypertension (39.1%), particu-
larly in the group who developed cardiac compli-
cations (42.3%), and prevalence of diabetes melli-
tus (6.3%). The prevalence of hypercholesterolaemia
(34.4%) and smoking (13.4%) seems to be relative-
ly low in our cohort as for the Polish population.
The mechanisms of trastuzumab-related car-
diotoxicity remain uncertain. Genetic background
has been suggested by some studies [34, 35]. The
clinical picture and the lack of diagnostic structur-
al findings on myocardial biopsy samples suggest
a totally different mechanism of myocardial dam-
age from that of anthracyclines [36]. There are two
different hypothesis of trastuzumab mechanism of
cardiac damage in the literature. Some preclinical
data indicate that inhibition of the myocardial HER2
receptor leads to changes in the tertiary structure
of the cardiac contractile apparatus, which seems
likely to be a reversible effect [37]. Others suggest
that trastuzumab induces apoptosis and car-
diomyocytes’ death, which is likely a progressive
and rather irreversible condition [38]. Both mecha-
nisms may play a role in cardiotoxicity and numer-
ous external factors may decide which predomi-
nates and whether heart damage is reversible.
The limitations of our study are its small sample
size and short follow-up. Longer term follow-up is
required to answer some unanswered questions
concerning the nature of trastuzumab cardiotoxic-
ity. (The follow-up of the population of our study 
is being conducted.) We analysed only the associ-
ation of cardiovascular risk factor with trastuzum-
ab-related cardiotoxicity, while numerous other 
situations that accompany cancer treatment (ra  d-
io therapy, left side of breast cancer, other anticancer
medications and their dosages, time from anthra-
cycline completion to trastuzumab initiation) are
known to influence cardiac damage during treat-
ment in oncology. They were not included in the
analysis. 
It is difficult to compare the incidence of asymp-
tomatic LV dysfunction in our population with that
in the cohorts of other studies as different LVEF cri-
teria of thresholds for trastuzumab cardiotoxicity
were used in particular studies. Also the modes of
LV function evaluation and LVEF calculation were
different in particular studies (echocardiography,
MUGA, CT, MRI). There is no international agree-
ment about the universal thresholds of LV function
for definition of trastuzumab cardiotoxicity [39]. 
In conclusion, nearly one in four patients will dis-
continue trastuzumab treatment due to cardiac
complications, among which LV dysfunction is the
most frequent. Although cardiac complications of
trastuzumab therapy are frequent, they seem not234 Arch Med Sci 2, April / 2012
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to be harmful. Most of them are transient, asymp-
tomatic and reversible, although there have been
reports on rare cases of progressing LV dysfunction
and HF. Nevertheless, longer follow-up is needed to
confirm that cardiotoxicity associated with tras  -
tuzumab therapy does not affect long-term out-
come. Prior to institution of trastuzumab therapy,
all patients should be evaluated for cardiovascular
status. As the majority of complications are asymp-
tomatic, routine cardiac monitoring should be per-
formed during trastuzumab treatment.
References
1. Hudziak RM, Ullrich A. Increased expression of the puta-
tive growth factor receptor p185HER2 causes transfor-
mation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad
Sci 1987; 84: 7159-63. 
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,
McGuire WL. Human breast cancer: correlation of relapse
and survival with amplification of the HER-2/neu onco-
gene. Science 1987; 235: 177-82.
3. Force T, Krause DS, Van Etten. Molecular mechanisms of
cardiotoxicity of tyrosine kinase inhibition. Nat Rev Can-
cer 2007; 7: 332-44.
4.  Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant
trastuzumab: a milestone in the treatment of HER-2 pos-
itive early. Oncologist 2006; 11 Suppl 1: 4-12. 
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Her-
ceptin Adjuvant (HERA) Trial Study Team. Trastuzumab
after adjuvant chemotherapy in HER2-positive breast can-
cer. N Engl J Med 2005; 353: 1659-72. 
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. FinHer
Study Investigators. Adjuvant docetaxel or vinorelbine
with or without trastuzumab for breast cancer. N Engl 
J Med 2006; 354: 809-20.
7. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-
up of trastuzumab plus adjuvant chemotherapy for oper-
able human epidermal growth factor receptor 2-positive
breast cancer: joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol 2011; 29: 3366-73. 
8. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction
in the trastuzumab clinical trials experience. J Clin Oncol
2002; 20: 1215-21.
9. Mackey JR, Clemons M, Cote MA, et al. Cardiac manage-
ment adjuvant trastuzumab therapy: recommendation
of the Canadian Working Group. Current Oncol 2008; 15:
24-35.
10. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of
cardiac health in trastuzumab-treated patients with breast
cancer: updated United Kingdom National Cancer
Research Institute recommendations for monitoring. 
Br J Cancer 2009; 100: 684-92.
11. Lang RM, Bierig M, Devereux RB, et al. Recommendations
for chamber quantification: a report from the American
Society of Echocardiography’s Guidelines and Standards
Committee and the Chamber Quantification Writing
Group, developed in conjunction with the European Asso-
ciation of chocardiography, a branch of the European Soci-
ety of Cardiology. J Am Soc Echocardiography 2005; 18:
1440-6.
12. Carver JR Carver JR. Management of trastuzumab-related
cardiac dysfunction. Prog Cardiovasc Dis 2010; 53: 130-9.
13. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the
diagnosis and treatment of chronic heart failure: full text
(update 2005). The task force for the diagnosis and treat-
ment of CHF of the European Society of Cardiology. Eur
Heart J 2005; 26: 1115-40.
14. Wysocki PJ, Hutka M. Cardiotoxicity of 5-fluorouracil in
a young colorectal cancer patient – case report and review
of literature. Arch Med Sci 2009; 5: 277-80.
15. Sparano JA, Brown DL, Wolff AC. Predicting cancer thera-
pyinduced cardiotoxicity. The role of troponins and other
markers. Drug Saf 2002; 25: 301-11.
16. Olin RL, Desai SS, Fox K Davidson Rl. Non-myopathic car-
diac events in two patients treated with trastuzumab.
Breast J 2007; 13: 211-2. 
17. ATu CM, Chu KM, Yang SP, Cheng SM, Wang WB.
Trastuzumab (Herceptin)-associated cardiomyopathy pre-
sented as new onset of complete left bundle-branch block
mimicking acute coronary syndrome: a case report and lit-
erature review. Am J Emerg Med 2009; 27: 903e1-3.
18. Oliveira M, Nave M, Gil N, Passos-Coelho JL. Sudden death
during adjuvant trastuzumab therapy of breast cancer.
Ann Oncol 2010; 21: 901.
19. Slamon D, Eiermann W, Robert N, -006 oboB BCIRG
006:2nd interim analysis chase III randomised trial com-
paring doxorubicine and cyclophosphamid followed by doc-
etaxel (AC/T) with doxorubicine and cyclo  phosphamid fol-
lowed by docetaxel and trastuzumab (AC/ETH) with
docetaxel, carboplatin and trastuzumab (TCH) in Her2neu
positive early breast cancer patients. In: Proceedings of San
Antonio breast cancer symposium (SABCS): 2006, San Anto-
nio. Breast Cancer Research and Treatment.
20. Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab
mediated cardiotoxicity in the setting of adjuvant
chemotherapy for breast cancer: a retrospective study.
Breast Cancer Res Treat 2009; 117: 357-64.
21. Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant
chemotherapy and cardiotoxicity in real-world women
with breast cancer. J Card Fail 2012; 18: 113-9.
22. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clin-
ical practice. N Engl J Med 2007; 357: 94-5.
23. Guarneri V, Lenihan DJ, Valero V, et al. Phase II study of
weekly paclitaxel and trastuzumab in anthracycline- and
taxane-pretreated patients with HER2-overexpressing
metastatic breast cancer. Br J Cancer 2004; 90: 36-40. 
24. Esteva FJ, Valero V, Booser D, et al. Phase II study of week-
ly docetaxel and trastuzumab for patients with HER-2-
overexpressing metastatic breast cancer. J Clin Oncol
2002; 20: 1800-8. 
25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast
cancer. N Engl J Med 2005; 353: 1673-84. 
26. Kelly H, Kimmick G, Dees EC, et al. Response and cardiac
toxicity of trastuzumab given in conjunction with week-
ly paclitaxel after doxorubicin/cyclophosphamide. Clin
Breast Cancer 2006; 7: 237-43. 
27. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of
cardiac dysfunction in a randomized trial comparing dox-
orubicin and cyclophosphamide followed by paclitaxel,
with or without trastuzumab as adjuvant therapy in node-
positive, human epidermal growth factor receptor 2-over  -
expressing breast cancer: NSABP B-31. J Clin Oncol 2005;
23: 7811-9.
28. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety
analysis of doxorubicin and cyclophosphamide followed
by paclitaxel with or without trastuzumab in the North
Central Cancer Treatment Group N9831 adjuvant breast
cancer trial. J Clin Oncol 2008; 26: 1231-8. 
29. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey
JR. Early breast cancer therapy and cardiovascular injury.
J Am Coll Cardiol 2007; 50: 1435-41.Arch Med Sci 2, April / 2012 235
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer 
overexpressing human epidermal growth factor receptor type 2 – a prospective study
30. Jones LW, Courneya KS, Fairey AS, Mackey JR. Effects of
an oncologist's recommendation to exercise on self-
reported exercise behavior in newly diagnosed breast can-
cer survivors: a single-blind, randomized controlled trial.
Ann Behav Med 2004; 28: 105-13. 
31. Irwin ML, McTiernan A, Baumgartner RN, et al. Changes
in body fat and weight after a breast cancer diagnosis:
influence of demographic, prognostic, and lifestyle fac-
tors. J Clin Oncol 2005; 23: 774-82.
32. Clarke CA, Purdie DM, Glaser SL. Population attributable
risk of breast cancer in white women associated with
immediately modifiable risk factors. BMC Cancer 2006;
6: 170-81.
33. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-
weight, obesity, and mortality from cancer in a prospec-
tively studied cohort of U.S. adults. N Engl J Med 2003;
348: 1625-38.
34. Hosseini M, Houshmand M, Ebrahimi A. MTHFR poly-
morphisms and breast cancer risk. Arch Med Sci 2011; 7:
134-7.
35. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The
role of polymorphisms within paraoxonases (192 Gln/Arg
in PON1 and 311Ser/Cys in PON2) in the modulation 
of cardiovascular risk: a pilot study. Angiology 2010; 61:
157-65.
36. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of
trastuzumab-related cardiotoxicity: new insights based
on clinical course and response to medical treatment.
J Clin Oncol 2005; 23: 7820-6.
37. Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2
by receptor tyrosine kinase inhibitors causes myofibrillar
structural damage without cell death in adult rat car-
diomyocytes. Exp Cell Res 2009; 315: 1302-12.
38. Singh KK, Shukla PC, Quan A, et al. Herceptin, a re  comb-
inant humanized anti-ERBB2 monoclonal antibody,
induces cardiomyocyte death. Biochem Biophys Res Com-
mun 2011; 411: 421-6.
39. Verma S, Ewer MS. Is cardiotoxicity being adequately
assessed in current trials of cytotoxic and targeted agents
in breast cancer? Ann Oncol 2011; 22: 1011-8.